LIXT.NASDAQLixte Biotechnology Holdings, INC

S-1/A: Lixte Biotechnology Files Amendment No. 1 to Form S-1 for Resale of Common Stock Issuable Upon Warrant Exercise

Sentiment:

S-1/A Amendment

📋All filings for Lixte Biotechnology Holdings, INC
🔒Login to Follow

Lixte Biotechnology Holdings files an amendment to its Form S-1 registration statement to correct a hyperlink and register shares for resale by selling stockholders upon exercise of warrants.

Delay expectedThe Institutional Review Board (the IRB) of the Netherlands Cancer Institute (NKI) has put the colorectal cancer study on hold.It is expected that it will take at least two months to prepare a detailed response to the IRB, during which time the Company intends to update the safety overview of LB-100.
Capital raiseThe company has entered into a Securities Purchase Agreement with two institutional investors, raising gross proceeds of approximately $1,050,000.The company is seeking to regain compliance with the Stockholders Equity Requirement, which outlined our proposed initiatives to regain compliance by raising equity capital through various registered equity offerings.
Worse than expectedThe company is not in compliance with Nasdaq's minimum stockholders' equity requirement.The principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating two SAEs observed in the clinical trial that was launched in August 2024.The Institutional Review Board (the IRB) of the Netherlands Cancer Institute (NKI) has put the colorectal cancer study on hold.

Summary

  • Lixte Biotechnology Holdings, Inc. has filed Amendment No. 1 to its Form S-1 registration statement, initially filed on April 4, 2025, to correct a hyperlink to the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
  • The registration statement covers the resale of 467,393 shares of common stock by selling stockholders, issuable upon the exercise of certain warrants.
  • These warrants include 434,784 shares of common stock issuable upon the exercise of outstanding 2025 Warrants and 32,609 shares of common stock issuable upon the exercise of 2025 Placement Agent Warrants.
  • Lixte will not receive any proceeds from the sale of common stock by the selling stockholders, but will receive proceeds upon the cash exercise of the 2025 Warrants or the 2025 Placement Agent Warrants.
  • The company's common stock is listed on The Nasdaq Capital Market under the symbol LIXT, and the last reported sale price on April 2, 2025, was $1.22 per share.
  • The company is a clinical-stage biopharmaceutical company focused on developing cancer therapies, primarily inhibitors of protein phosphatase 2A (PP2A).
  • The company's lead drug candidate, LB-100, is currently being tested in clinical trials for various cancers, including Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon Cancer, and Advanced Soft Tissue Sarcoma.
  • The company has a history of losses and relies on equity capital to fund its operating requirements.
  • The company is currently not in compliance with the Nasdaq continued listing requirements and is seeking to regain compliance.
  • The company has entered into several clinical trial agreements with institutions such as the Spanish Sarcoma Group, MD Anderson Cancer Center, and the Netherlands Cancer Institute to evaluate LB-100 in combination with other therapies.
  • The company has an exclusive Patent License Agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) for intellectual property rights related to LB-100.

Sentiment

Score: 4

Explanation: The document contains both positive and negative aspects. The company is advancing its clinical trials and has secured partnerships, but it also faces financial challenges, regulatory hurdles, and potential clinical trial delays. The overall sentiment is cautiously optimistic.

Positives

  • LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma.
  • The company has an exclusive Patent License Agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) for intellectual property rights related to LB-100.
  • The company has entered into several clinical trial agreements with institutions such as the Spanish Sarcoma Group, MD Anderson Cancer Center, and the Netherlands Cancer Institute to evaluate LB-100 in combination with other therapies.

Negatives

  • The company has a history of losses and relies on equity capital to fund its operating requirements.
  • The company is currently not in compliance with the Nasdaq continued listing requirements and is seeking to regain compliance.
  • The principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating two SAEs observed in the clinical trial that was launched in August 2024.
  • The Institutional Review Board (the IRB) of the Netherlands Cancer Institute (NKI) has put the colorectal cancer study on hold.

Risks

  • Investing in the company's common stock is highly speculative and involves a significant degree of risk.
  • A clinical trial hold due to serious adverse events could delay or halt the development of the company's product candidate.
  • The company is currently not in compliance with the Nasdaq continued listing requirements, and delisting could negatively impact the company.
  • The company will have to seek to raise additional funds to fund its operations, including the various clinical trials being currently conducted or will be conducted in the future.
  • The price of the company's common stock or warrants might fluctuate substantially.

Future Outlook

The company's longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical companies with major programs in cancer. The company intends to take reasonable measures available to regain compliance under Nasdaq's listing rules and to remain listed on Nasdaq.

Industry Context

Lixte Biotechnology operates in the competitive biopharmaceutical industry, focusing on cancer therapies. The company's approach involves identifying new targets for drug development and commercializing cancer therapies. The company's focus on PP2A inhibitors aligns with the industry's interest in novel mechanisms for enhancing existing cancer treatments.

Comparison to Industry Standards

  • Lixte Biotechnology is a clinical-stage company, similar to other small-cap biotech firms such as Veru Inc. and GT Biopharma, Inc., which are also focused on developing novel cancer therapies.
  • The company's approach of combining its lead compound with existing treatments like chemotherapy and immunotherapy is a common strategy in the industry to improve efficacy and overcome resistance.
  • The company's reliance on partnerships and collaborations with academic institutions and pharmaceutical companies is also a typical model for small biotech firms to leverage external expertise and resources.
  • The company's financial situation, with a history of losses and reliance on equity financing, is common among clinical-stage biotech companies, which often require significant capital to fund research and development activities.
  • The company's efforts to regain compliance with Nasdaq listing requirements are similar to those of other companies facing delisting risks, such as raising capital, implementing cost-cutting measures, or seeking strategic alternatives.

Stakeholder Impact

  • Shareholders face the risk of dilution and potential loss of investment due to the company's financial situation and need for additional capital.
  • Employees' job security could be affected by the company's financial stability and ability to continue operations.
  • Patients may benefit from the development of new cancer therapies, but also face risks associated with clinical trials and potential adverse events.
  • Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

  • The company intends to take reasonable measures available to regain compliance under Nasdaq's listing rules and to remain listed on Nasdaq.
  • The company intends to update the safety overview of LB-100.
  • The company will prepare a detailed response to the IRB.

Key Dates

DateDescription
March 22, 2006Initial Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurologic Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).
July 31, 2019Effective date of Collaboration Agreement with the Spanish Sarcoma Group (GEIS) for an Investigator-Initiated Clinical Trial.
March 9, 2021Clinical trial of LB-100 combined with an FDA-approved standard regiment for treatment of untreated extensive-stage disease small cell lung cancer was initiated.
October 8, 2021Entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (NKI), and Oncode Institute, Utrecht, for a term of three years.
October 13, 2022Announced that the Spanish Agency for Medicines and Health Products (AEMPS) had authorized a Phase 1b/randomized Phase 2 study of LB-100, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS).
June 2, 2023Effected a one-for-ten reverse split of outstanding shares of common stock.
June 30, 2023The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose of the combination of doxorubicin and LB-100.
July 20, 2023Sold 583,334 shares of common stock at $6.00 per share, raising gross proceeds of approximately $3,500,000.
September 20, 2023Announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to dostarlimab-gxly may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).
October 3, 2023Entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000 Euros to the operating budget being funded by us.
September 30, 2024The recruitment phase of the Phase 1b portion of the protocol was completed during the quarter ended September 30, 2024.
October 4, 2024Entered into Amendment No. 3 to the Development Collaboration Agreement with NKI, which suspended Amendment No. 2 and provided for a new study term of one year and starts upon the dosing of the first patient in the clinical trial at a project cost of 100,000 Euros.
June 10, 2024Entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (NKI) to conduct a Phase 1b clinical trial of LB-100, combined with atezolizumab, for patients with microsatellite stable metastatic colon cancer.
August 2024The clinical trial opened in August 2024 with the enrollment of the first patient.
August 19, 2024Received a letter from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement.
October 3, 2024Submitted a plan to Nasdaq to regain compliance with the Stockholders Equity Requirement.
October 21, 2024Received notice from Nasdaq granting an extension through February 18, 2025, to regain compliance with the Stockholders Equity Requirement.
January 29, 2024Announced the entry of the first patient into the clinical trial at MD Anderson Cancer Center.
February 11, 2025Entered into a Securities Purchase Agreement with two institutional investors.
February 13, 2025Sold 434,784 shares of common stock at $2.415 per share, raising gross proceeds of approximately $1,050,000.
February 18, 2025Did not regain compliance with the Stockholders Equity Requirement.
February 19, 2025Received a Staff determination letter from Nasdaq stating that the company did not meet the terms of the extension because it did not complete its proposed financing initiatives to regain compliance.
February 23, 2024Entered into a Patent License Agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI).
February 25, 2025Announced that the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Companys proprietary compound LB-100 with GSKs dostarlimab to treat ovarian clear cell cancer.
March 11, 2025Entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved us of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration Agreement of approximately $3,095,000.
April 2, 2025The last reported sale price for the company's common stock was $1.22 per share.
April 4, 2025Initial filing date of the Registration Statement on Form S-1.
April 9, 2025Date of the prospectus.
December 31, 2025We expect to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.
December 31, 2026Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared by December 31, 2026.
December 31, 2027We currently expect that this clinical trial will be completed by December 31, 2027.
July 20, 2028The 2023 Warrants expire five years thereafter on July 20, 2028.
February 13, 2030Such Warrants had an initial exercise price of $2.29 per share, were immediately exercisable upon issuance, and expire five years thereafter on February 13, 2030.

Keywords

LB-100, warrants, clinical trials, biotechnology, cancer, LIXT, PP2A, Nasdaq, registration statement, common stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.